- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06422884
Eine Phase-2-Studie mit ENV-101 bei Patienten mit Lungenfibrose (WHISTLE-PF-Studie)
Eine multizentrische, randomisierte, doppelblinde, kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von ENV-101 bei Patienten mit Lungenfibrose (WHISTLE-PF-Studie)
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This trial is a 6-month, randomized, double-blind, controlled, dose-ranging trial of ENV-101 in adult patients with idiopathic pulmonary fibrosis (IPF). Patients are allowed to continue treatment with approved standard of care (e.g., nintedanib, pirfenidone) during the trial. Patients will be randomized to one of 3 dose levels of ENV-101 or placebo at baseline. The objectives of this trial are to characterize the efficacy, antifibrotic activity, and safety of ENV-101 to select the Phase 3 dose of ENV-101.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Buenos Aires, Argentinien, C1426ABP
- Research Site
-
Buenos Aires, Argentinien, 1888
- Research Site
-
Mendoza, Argentinien, 5501
- Research Site
-
Mendoza, Argentinien, CP 5500
- Research Site
-
-
Buenos Aires
-
Quilmes, Buenos Aires, Argentinien, B1878FNR
- Research Site
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Research Site
-
Macquarie Park, New South Wales, Australien, 2109
- Research Site
-
-
Queensland
-
Brisbane, Queensland, Australien, 4032
- Research Site
-
South Brisbane, Queensland, Australien, 4101
- Research Site
-
-
Victoria
-
Box Hill, Victoria, Australien, 3128
- Research Site
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Research Site
-
-
-
-
-
Brussels, Belgien, 1200
- Research Site
-
Brussels, Belgien, 1070
- Research Site
-
-
Namur
-
Dinant, Namur, Belgien, 5500
- Research Site
-
-
-
-
-
Berlin, Deutschland, 13125
- Research Site
-
Leipzig, Deutschland, 4103
- Research Site
-
-
Hesse
-
Giessen, Hesse, Deutschland, 35398
- Research Site
-
Immenhausen, Hesse, Deutschland, 34376
- Research Site
-
-
Lower Saxony
-
Hanover, Lower Saxony, Deutschland, 30625
- Research Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Deutschland, 45239
- Research Site
-
-
-
-
-
Angers, Frankreich, 49933
- Research Site
-
Bordeaux, Frankreich, 33604
- Research Site
-
Caen, Frankreich, 14033
- Research Site
-
Dijon, Frankreich, 21000
- Research Site
-
Montpellier, Frankreich, 34090
- Research Site
-
Nantes, Frankreich, 44093
- Research Site
-
Paris, Frankreich, 75014
- Research Site
-
Paris, Frankreich, 94270
- Research Site
-
Rennes, Frankreich, 35033
- Research Site
-
Tours, Frankreich, 37044
- Research Site
-
-
-
-
-
Dublin, Irland, D04 T6F4
- Research Site
-
-
Leinster
-
Dublin, Leinster, Irland, D05 AT88
- Research Site
-
Dublin, Leinster, Irland, D07 A8NN
- Research Site
-
-
Munster
-
Cork, Munster, Irland, T12 DC4A
- Research Site
-
-
-
-
-
Catania, Italien, 95123
- Research Site
-
Milan, Italien, 20123
- Research Site
-
Turin, Italien, 10126
- Research Site
-
-
Forli-Cesena
-
Bologna, Forli-Cesena, Italien, 47121
- Research Site
-
-
Padua
-
Padova, Padua, Italien, 35128
- Research Site
-
-
Tuscany
-
Florence, Tuscany, Italien, 50314
- Research Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 2C8
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6Z 2K5
- Research Site
-
-
Ontario
-
Ajax, Ontario, Kanada, L1S 2J5
- Research Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 0A9
- Research Site
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Research Site
-
Trois-Rivières, Quebec, Kanada, G8T 7A1
- Research Site
-
-
-
-
Selangor
-
Kuala Lumpur, Selangor, Malaysia, 42300
- Research Site
-
Kuala Lumpur, Selangor, Malaysia, 50590
- Research Site
-
Kuala Lumpur, Selangor, Malaysia, 56000
- Research Site
-
-
-
-
-
Chihuahua City, Mexiko, 31230
- Research Site
-
Mexico City, Mexiko, 14080
- Research Site
-
Oaxaca City, Mexiko, 68000
- Research Site
-
Puebla City, Mexiko, 72180
- Research Site
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexiko, 64060
- Research Site
-
Monterrey, Nuevo León, Mexiko, 64718
- Research Site
-
San Nicolás de los Garza, Nuevo León, Mexiko, 66465
- Research Site
-
-
Querétaro
-
San Juan del Río, Querétaro, Mexiko, 76800
- Research Site
-
-
-
-
-
Auckland, Neuseeland
- Research Site
-
Christchurch, Neuseeland, 8011
- Research Site
-
Hamilton, Neuseeland
- Research Site
-
-
-
-
-
Seoul, Südkorea, 16499
- Research Site
-
-
(Deogyang District)
-
Seoul, (Deogyang District), Südkorea, 10475
- Research Site
-
-
(Dong District)
-
Ulsan, (Dong District), Südkorea, 44033
- Research Site
-
-
(Haeundae District)
-
Busan, (Haeundae District), Südkorea, 48108
- Research Site
-
-
(Seongbuk District)
-
Seoul, (Seongbuk District), Südkorea, 02841
- Research Site
-
-
(Songpa District)
-
Seoul, (Songpa District), Südkorea, 05505
- Research Site
-
-
(Yongsan District)
-
Seoul, (Yongsan District), Südkorea, 04401
- Research Site
-
-
-
-
-
Belfast, Vereinigtes Königreich, BT9 7AB
- Research Site
-
Birmingham, Vereinigtes Königreich, B9 5SS
- Research Site
-
Birmingham, Vereinigtes Königreich, B15 2GW
- Research Site
-
Cambridge, Vereinigtes Königreich, CB2 0AY
- Research Site
-
Edinburgh, Vereinigtes Königreich, EH1 3EG
- Research Site
-
Exeter, Vereinigtes Königreich, EX2 5DW
- Research Site
-
Leicester, Vereinigtes Königreich, LE3 9QP
- Research Site
-
London, Vereinigtes Königreich, SW3 6NP
- Research Site
-
Londonderry, Vereinigtes Königreich, BT47 6SB
- Research Site
-
-
-
-
-
Vienna, Österreich, 1090
- Research Site
-
-
Styria
-
Graz, Styria, Österreich, 8036
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients ≥ 40 years old with an IPF diagnosis as confirmed by the Investigator.
- Percent predicted FVC of ≥ 45% at study start.
- Percent predicted diffusing capacity of lung for carbon monoxide (DLCO) ≥ 25%, adjusted for hemoglobin (Hgb) at study start.
- Ability to perform spirometry tests.
- Either stable treatment with standard of care (SoC) [i.e., antifibrotics, immunosuppressants (PPF only)] for at least 3 months prior to study start or not treated with SoC for at least 8 weeks prior to study start.
Exclusion Criteria:
-
Evidence of other known causes of interstitial lung disease (ILD).
-
Forced expiratory volume in one second (FEV1)/FVC ratio <0.7 at study start.
-
History of malignancy, including carcinoma during the preceding 5 years from study start, with the following exceptions:
- Prior history of in situ melanoma, basal or squamous cell skin cancer if treated with curative therapy.
- Patients with prostate cancer that are managed by surveillance.
- Patients with ductal carcinoma in situ, treated surgically with curative intent.
-
Patients with moderate to severe hepatic impairment (Child-Pugh B and C).
-
Smoking (including vaping) within 6 months of study start; current smoker, or unwillingness to refrain from smoking during the clinical trial duration.
-
Active or suspected alcohol or drug abuse in the opinion of the Investigator.
-
Currently enrolled in another investigational device or drug trial, or less than 3 months from study start since ending another investigational device or drug trial(s) or receiving other investigational treatment(s).
-
Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV).
-
Major surgery requiring hospitalization (according to the Investigator) performed within 3 months prior to study start or planned during the course of the trial. Being on a transplant list is allowed.
-
Occurrence of serious illness requiring hospitalization within 90 days prior to study start.
-
Current or previous use (within 28 days prior to study start) of the following:
- Endothelin receptor antagonist
- Riociguat
- Prostacyclin or prostacyclin analogue
- Radiation to the lungs
- Oral corticosteroids >15 mg/day
-
Use of cyclophosphamide or tocilizumab within 8 weeks, or rituximab within 6 months, prior to study start.
-
Use of drugs that are known moderate or stronger CYP3A4 inhibitors or inducers within 14 days prior to study start. Patients must also agree not to eat fruits that inhibit CYP3A4 such as grapefruit, Seville oranges, pomelo and star fruit.
-
Patients of reproductive potential who are sexually active and unwilling to use birth control for the duration of the study and for 3 months after their final dose of study drug.
-
Females that are pregnant or nursing.
-
Patients that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final dose of study drug.
-
Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final dose of study drug.
-
Patients with a history of a severe allergic reaction or anaphylactic reaction or known hypersensitivity to any component of ENV-101.
-
Patients who have previously taken ENV-101.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: ENV-101 Niedrige Dosis (IPF-Population)
|
oral tablet, dosed once a day
Andere Namen:
|
|
Experimental: ENV-101 mittlere Dosis (IPF-Population)
|
oral tablet, dosed once a day
Andere Namen:
|
|
Experimental: ENV-101 hohe Dosis (IPF-Population)
|
oral tablet, dosed once a day
Andere Namen:
|
|
Placebo-Komparator: Placebo (IPF-Population)
|
oral tablet, dosed once a day |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in percent predicted forced vital capacity (ppFVC) compared to placebo
Zeitfenster: Baseline and Week 24
|
ppFVC is a measure of lung function |
Baseline and Week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Zeit bis zur Krankheitsprogression (absoluter Rückgang der ppFVC > 10 %, IPF-bedingter Krankenhausaufenthalt oder Tod) im Vergleich zu Placebo
Zeitfenster: Ausgangswert und Woche 24
|
Ausgangswert und Woche 24
|
|
|
Absolute Veränderung der prozentualen quantitativen interstitiellen Lungenerkrankung (QILD) durch HRCT-Bildgebung des Brustkorbs im Vergleich zu Placebo im Vergleich zu Placebo
Zeitfenster: Ausgangswert und Woche 24
|
Ausgangswert und Woche 24
|
|
|
Absolute Veränderung der prozentualen quantitativen Milchglastrübung (QGG) durch HRCT-Bildgebung des Brustkorbs im Vergleich zu Placebo
Zeitfenster: Ausgangswert und Woche 24
|
Ausgangswert und Woche 24
|
|
|
Absolute Veränderung der prozentualen quantitativen Lungenfibrose (QLF) durch HRCT-Bildgebung des Brustkorbs im Vergleich zu Placebo
Zeitfenster: Ausgangswert und Woche 24
|
Ausgangswert und Woche 24
|
|
|
Absolute change in FVC (mL) compared to placebo
Zeitfenster: Baseline and Week 24
|
FVC is a measure of lung function |
Baseline and Week 24
|
|
Absolute change in the Living with Pulmonary Fibrosis Symptoms (L-PF Symptoms) Questionnaire Cough domain score compared to placebo
Zeitfenster: Baseline and Week 24
|
The L-PF Symptoms Questionnaire Cough domain consists of 6 questions regarding a subject's experience with cough over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Cough domain is normalized to the range 0 to 100, with higher scores indicating greater impairment. |
Baseline and Week 24
|
|
Absolute change in the L-PF Symptoms Questionnaire Dyspnea domain score compared to placebo
Zeitfenster: Baseline and Week 24
|
The L-PF Symptoms Questionnaire Dyspnea domain consists of 12 questions regarding a subject's experience with dyspnea (shortness of breath) over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Dyspnea domain is normalized to the range 0 to 100, with higher scores indicating greater impairment. |
Baseline and Week 24
|
|
Absolute change in the L-PF Symptoms Questionnaire Fatigue domain score compared to placebo
Zeitfenster: Baseline and Week 24
|
The L-PF Symptoms Questionnaire Fatigue domain consists of 5 questions regarding a subject's experience with fatigue over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Fatigue domain is normalized to the range 0 to 100, with higher scores indicating greater impairment. |
Baseline and Week 24
|
|
Absolute change in the L-PF Symptoms module score compared to placebo
Zeitfenster: Baseline and Week 24
|
The L-PF Symptoms module is a 23-item patient-reported outcome measure designed to assess the severity of dyspnea (12 items), cough (6 items), and fatigue (5 items) experienced by a subject over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Symptoms module is normalized to the range 0 to 100, with higher scores indicating greater impairment. |
Baseline and Week 24
|
|
Absolute change in the L-PF Impacts module score compared to placebo
Zeitfenster: Baseline and Week 24
|
The L-PF Impacts module consists of 21 questions regarding a subject's experience with the impacts of pulmonary fibrosis on daily life over the prior week. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Impacts module domain is normalized to the range 0 to 100, with higher scores indicating greater impairment. |
Baseline and Week 24
|
|
Absolute change in total lung capacity (TLC) by chest high-resolution computed tomography (HRCT) imaging compared to placebo
Zeitfenster: Baseline and Week 24
|
HRCT is a method of imaging which is more precise than chest x-ray in the diagnosis and monitoring of diseases of the lung tissue and the airways. |
Baseline and Week 24
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Lisa Lancaster, M.D., Endeavor Biomedicines
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- ENV-IPF-103
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .